ABSTRACT
Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in patients over the age of 60 in developed countries (1). With the expected increase in the aged population and age-related eye diseases due to increased life expectancies, signifi - cant efforts are being made to better understand and treat AMD. While anti-vascular endothelial growth factor agents have been successfully utilized to combat neovascular AMD, there is still much need for improved management of non-neovascular AMD.
